Mirle Schemionek

Rheinbach, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

USP8 controls proteostasis pathways in B cells and multiple myeloma.

USP8 controls proteostasis pathways in B cells and multiple myeloma.

Journal: Leukemia
Published: April 09, 2026

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa.

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alfa.

Journal: Blood advances
Published: January 08, 2024

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients.

Myelofibrosis at diagnosis is associated with the failure of treatment-free remission in CML patients.

Journal: Frontiers in pharmacology
Published: April 26, 2023

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma.

Journal: Drug delivery and translational research
Published: November 23, 2022

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.

Targeting cytokine-induced leukemic stem cell persistence in chronic myeloid leukemia by IKK2-inhibition.

Journal: Haematologica
Published: March 10, 2022

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia.

Journal: PloS one
Published: November 05, 2021

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.

The Unfolded Protein Response Is a Major Driver of LCN2 Expression in BCR-ABL- and JAK2V617F-Positive MPN.

Journal: Cancers
Published: June 04, 2021

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.

Therapeutic inhibition of FcγRIIb signaling targets leukemic stem cells in chronic myeloid leukemia.

Journal: Leukemia
Published: March 16, 2020

Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.

Targeting of BCR-ABL1 and IRE1α induces synthetic lethality in Philadelphia-positive acute lymphoblastic leukemia.

Journal: Carcinogenesis
Published: November 29, 2019

Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms.

Transcriptional alteration of DNA repair genes in Philadelphia chromosome negative myeloproliferative neoplasms.

Journal: Annals of hematology
Published: July 31, 2019

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

LCP1 triggers mTORC2/AKT activity and is pharmacologically targeted by enzastaurin in hypereosinophilia.

Journal: Molecular carcinogenesis
Published: July 22, 2019

Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies.

Comparison of flow-FISH and MM-qPCR telomere length assessment techniques for the screening of telomeropathies.

Journal: Annals of the New York Academy of Sciences
Published: May 26, 2019
Showing 1-12 of 33

Last Updated: 09/26/2026